Orgenesis Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Safier Jacob, was filed 04 Dec 2024.
Orgenesis Inc.: what insiders have been doing
Orgenesis Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). No insider at Orgenesis Inc. has published a filing in the past twelve months. The most recent one dates from 4 December 2024.
The full history, which starts in 2011, counts 37 purchases against 11 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Since the insiders bought
- -67.9%Entry US$4.80 · Close at T+365 US$1.54
- -52.7%Entry US$51.80 · Close at T+365 US$24.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
- 10,000 shares@ US$0.51352.1% of flowCommon StockSEC:0000921895-24-002878:2Canonical exit: 15 Jul 2024 (T+90)
- 10,000 shares@ US$0.582.3% of flowCommon StockSEC:0000921895-24-002878:4Canonical exit: 22 Sept 2024 (T+90)
- 10,000 shares@ US$0.54442.2% of flowCommon StockSEC:0000921895-24-002878:1
- 10,000 shares@ US$0.50012.0% of flowCommon StockSEC:0000921895-24-002878:3
- 10,000 shares@ US$0.58142.3% of flowCommon StockSEC:0000921895-24-002878:5
- 10,000 shares@ US$0.594847.1% of flowCommon StockSEC:0000921895-24-002878:0Canonical exit: 9 Jul 2024 (T+90)
- 25,000 shares@ US$0.50100.0% of flowCommon StockSEC:0001493152-24-012669:0
- 100,000 shares@ US$0.689527.7% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:1Canonical exit: 20 Dec 2023 (T+90)
- 25,000 shares@ US$0.67126.8% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:2Canonical exit: 27 Dec 2023 (T+90)
- 10,000 shares@ US$0.8033.3% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:3Canonical exit: 3 Jan 2024 (T+90)
- 5,100 shares@ US$0.92761.9% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:4Canonical exit: 4 Jan 2024 (T+90)
- 603 shares@ US$0.86080.2% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:5Canonical exit: 8 Jan 2024 (T+90)
- 10,000 shares@ US$0.89993.6% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:6Canonical exit: 22 Jan 2024 (T+90)
- 500 shares@ US$0.87520.2% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:7Canonical exit: 23 Jan 2024 (T+90)
- 500 shares@ US$0.93050.2% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:8Canonical exit: 25 Jan 2024 (T+90)
- 5,000 shares@ US$0.73811.5% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:9Canonical exit: 29 Jan 2024 (T+90)
- 3,437 shares@ US$0.80561.1% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:10Canonical exit: 30 Jan 2024 (T+90)
- 20,000 shares@ US$0.84446.8% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:11Canonical exit: 31 Jan 2024 (T+90)
- 20,000 shares@ US$0.70945.7% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:12Canonical exit: 6 Feb 2024 (T+90)
- 20,000 shares@ US$0.65275.2% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:13Canonical exit: 7 Feb 2024 (T+90)
- 1,184 shares@ US$0.58080.3% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:14Canonical exit: 8 Feb 2024 (T+90)
- 5,800 shares@ US$0.51011.2% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:15Canonical exit: 19 Feb 2024 (T+90)
- 5,000 shares@ US$0.54021.1% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:16Canonical exit: 22 Feb 2024 (T+90)
- 1,016 shares@ US$0.45950.2% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:17Canonical exit: 29 Feb 2024 (T+90)
- 2,000 shares@ US$0.53090.4% of flowCommon Stock (par value $0.01)SEC:0001193805-24-000230:18Canonical exit: 10 Mar 2024 (T+90)
25 of 53 declarations
About Orgenesis Inc.
Orgenesis Inc. is a U.S.-based biotechnology company focused on decentralized cell and gene therapy manufacturing and commercialization. The company is headquartered in Germantown, Maryland, United States. Historically, Orgenesis was listed on the NASDAQ under the ticker ORGS; more recently, the stock has traded on the OTC market following its 2025 Nasdaq delisting. From an equity analyst’s perspective, Orgenesis should be viewed as a niche advanced-therapy platform company rather than a traditional drug developer.
The company’s core strategy is built around its POCare platform, which is intended to bring cell and gene therapies closer to the point of care. Orgenesis positions this platform as a way to reduce the cost, complexity, and logistical burden associated with personalized therapies. Its model is organized around three main components. POCare Therapies is the therapeutic pipeline and partnering layer, where Orgenesis seeks promising early-stage programs and brings development and validation in-house. POCare Technologies covers customized, automated processing systems designed to support scalable, GMP-compliant production. POCare Network is the collaboration layer, linking Orgenesis with academic institutions, hospitals, and biotech partners to support development, production, and eventual distribution.
Read moreShow less
A key part of the company’s differentiation is its focus on decentralized manufacturing infrastructure, including Orgenesis Mobile Processing Units and Labs (OMPUL). These mobile or modular processing concepts are designed to standardize production environments and shorten implementation timelines, which is important in an industry where centralized manufacturing can be expensive and operationally rigid. In practical terms, Orgenesis is trying to create a harmonized, reproducible framework for advanced therapy manufacturing that can be deployed locally.
Orgenesis targets several therapeutic areas, including immuno-oncology, viral diseases, metabolic and autoimmune disorders, vascular and musculoskeletal diseases, and kidney disease. That said, investors should note that the company remains in a high-risk category, with execution dependent on partner adoption, regulatory progress, funding availability, and successful commercialization of platform assets.
Recent developments have included continued restructuring around the public listing status after Nasdaq delisting, as well as financing-related disclosures and governance changes in recent SEC materials. For French-speaking investors evaluating U.S.-listed healthcare microcaps, Orgenesis offers a differentiated technology story in Santé & Pharma, but one that carries material dilution, liquidity, and execution risk.
